Premium
Multiple cytokines sharing the common receptor γ chain can induce CD154/CD40 ligand expression by human CD4 + T lymphocytes via a cyclosporin A‐resistant pathway
Author(s) -
Fayen John D.
Publication year - 2001
Publication title -
immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.297
H-Index - 133
eISSN - 1365-2567
pISSN - 0019-2805
DOI - 10.1046/j.1365-2567.2001.01296.x
Subject(s) - cd154 , cd40 , t cell receptor , biology , cd3 , t cell , microbiology and biotechnology , jurkat cells , immune system , immunology , cytotoxic t cell , cd8 , biochemistry , in vitro
Summary Expression of CD154/CD40 ligand (CD154/CD40L), an important molecular component of CD4 + T‐cell help, can be triggered by T‐cell receptor (TCR) stimulation. Dephosphorylation of the transcriptional element Nuclear Factor of Activated T cells‐1 (NFAT1) is a critical activation step in the TCR‐initiated signal transduction cascade which promotes CD154/CD40L expression. Cyclosporin A (CsA), which interferes with NFAT1 activation, has been shown to be an effective inhibitor of TCR‐triggered CD154/CD40L expression by resting T cells. We now report that recombinant interleukin‐2 (rIL‐2) is also capable of inducing CD154/CD40L on CD4 + T lymphoblasts via a pathway triggered independently of the CD3/TCR receptor complex. Recombinant IL‐2‐mediated CD154/CD40L expression, in contrast to that triggered by CD3/TCR stimulation, is only partially inhibited by CsA. The capacity of rIL‐2 to induce CD154/CD40L expression by T lymphoblasts also extends to a restricted number of cytokines sharing the cytokine receptor common γ chain, including IL‐15, and, to a lesser extent, IL‐7, but not IL‐4. A similar CsA‐resistant CD154/CD40L induction pathway can be triggered in primary T cells by the combination of anti‐CD3 stimulation and recombinant lymphokines. In contrast to T lymphoblasts, the CsA‐resistant CD154/CD40L induction in primary lymphocytes can be efficiently triggered by multiple cytokines which bind the common γ chain receptor family. The data outline a novel pathway of CD154/CD40L induction which is, at least in part, independent of NFAT1 and resistant to CsA. A more complete understanding of the mechanisms governing CD154/CD40L expression may facilitate the rational design of specifically targeted immunotherapeutic agents.